Sandoz has recently gained FDA approval for the 1st and only denosumab biosimilars.
- Denosumab is a bone anti-resorptive (slow down bone loss) drug. It is effective in addressing both primary and secondary bone loss, including conditions like osteoporosis.
- Osteoporosis is a condition in which bones become weak and brittle. The body constantly absorbs and replaces bone tissue. With osteoporosis, new bone creation doesn't keep up with old bone removal.
About Biosimilars
- A biosimilar is a biologic medical product that is almost identical to an original product.
- Biosimilars are manufactured using the same raw materials and manufacturing techniques as the original biological product.
- Biosimilars are approved versions of original ‘innovator’ products and can be manufactured when the original product's patent expires.
- They are approved by demonstrating their high similarity to an already approved biologic product, known as a reference product.
- Biosimilars share the same treatment risks and benefits as biologic medicines.
- Biosimilars offer the advantage of increased access to lifesaving medications at potentially lower costs.
- Biosimilars are more complex to manufacture compared to small-molecule generic medicines.
Difference between Biosimilars and Generics
Biosimilars
|
Generics
|
Involve creating equivalents of biological entities
|
Involve replicating chemical entities known as Active Pharmaceutical Ingredients (APIs)
|
Require engineering organisms for therapeutic effect
|
Can simply produce copies of the API
|
More complex in structure and manufacturing processes
|
Less complex compared to biosimilars
|
Regulatory approval is more complex compared to generics
|
Regulatory approval is less complex than for biosimilars
|
Trickier to copy due to complexity and potential structural differences
|
-
|
Prospects of Biosimilars
- The growth of biologics, especially for cancer, diabetes, and autoimmune diseases, has created a global opportunity for biosimilars.
- Indian pharmaceutical companies are investing heavily in biosimilar development and production to gain a competitive advantage.
- In 2014, Zydus Cadila made history by launching the world’s first biosimilar of Adalimumab, a drug used to treat rheumatoid arthritis and other autoimmune disorders, originally patented by AbbVie.
- Rheumatoid arthritis (RA) is a chronic (long-lasting) autoimmune disease that mostly affects joints.
- Autoimmune diseases occur when the immune system attacks healthy cells in the body.
- Biosimilars offer a cheaper option compared to biologics, making treatment more accessible to patients.
- Patent expirations of certain biologics, along with upcoming ones, create an opportunity to close the gap with biosimilars.
- Biosimilars can aid in battling diseases like cancer, asthma, and arthritis in developing countries, improving public health.
- Promoting biosimilars and complex generics production can help tackle the increasing prevalence of non-communicable diseases globally.
- The biosimilars industry provides a platform for pharmaceutical companies to innovate, succeed, and generate revenue while addressing crucial healthcare needs.
Active Pharmaceutical Ingredients (APIs)
- APIs are the essential elements in a pharmaceutical drug that cause the necessary effect on the body for treating a condition.
- Chemical compounds undergo processing to produce APIs.
- In a biologic drug, the active ingredient is termed a bulk process intermediate (BPI).
- In drug development and manufacturing, APIs are crucial active elements interacting with specific receptors or target molecules in the body to achieve the desired physiological or therapeutic response.
- All drugs consist of two fundamental parts: (1) Active Pharmaceutical Ingredient (API), the core ingredient, and (2) excipients.
- Excipients are substances, other than the drug, aiding in delivering the medication into your system.
- Chemically inactive substances like lactose or mineral oil serve as excipients.
- These materials contribute to maintaining the stability of the medication and controlling absorption when taking the drug.
|